Rating History for Ascendis Pharma (ASND) by JPMorgan
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 5/20/2026 | Jessica Fye | New Coverage | Overweight (N/A) |
295.00 (N/A) |
237.64 (230.83) |
-2.87% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 5/20/2026 | Jessica Fye | New Coverage | Overweight (N/A) |
295.00 (N/A) |
237.64 (230.83) |
-2.87% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||